These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 19604256)
1. Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development. Rhee EG; Barouch DH Clin Exp Immunol; 2009 Aug; 157(2):174-80. PubMed ID: 19604256 [TBL] [Abstract][Full Text] [Related]
2. Development of targeted adjuvants for HIV-1 vaccines. Liu J; Ostrowski M AIDS Res Ther; 2017 Sep; 14(1):43. PubMed ID: 28893282 [TBL] [Abstract][Full Text] [Related]
3. Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines. Ahlers JD; Belyakov IM Trends Mol Med; 2009 Jun; 15(6):263-74. PubMed ID: 19487159 [TBL] [Abstract][Full Text] [Related]
4. Toll or toll-free adjuvant path toward the optimal vaccine development. Ishii KJ; Akira S J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119 [TBL] [Abstract][Full Text] [Related]
5. Modulation of HIV-1 immunity by adjuvants. Moody MA Curr Opin HIV AIDS; 2014 May; 9(3):242-9. PubMed ID: 24670321 [TBL] [Abstract][Full Text] [Related]
6. Improving defences at the portal of HIV entry: mucosal and innate immunity. Shattock RJ; Haynes BF; Pulendran B; Flores J; Esparza J; PLoS Med; 2008 Apr; 5(4):e81. PubMed ID: 18384232 [TBL] [Abstract][Full Text] [Related]
7. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Maisonneuve C; Bertholet S; Philpott DJ; De Gregorio E Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12294-9. PubMed ID: 25136133 [TBL] [Abstract][Full Text] [Related]
8. Innate immunity in the control of HIV/AIDS: recent advances and open questions. Ploquin MJ; Jacquelin B; Jochems SP; Barré-Sinoussi F; Müller-Trutwin MC AIDS; 2012 Jun; 26(10):1269-79. PubMed ID: 22472855 [TBL] [Abstract][Full Text] [Related]
9. Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity. Kaufman DR; Barouch DH Clin Exp Immunol; 2009 Aug; 157(2):165-73. PubMed ID: 19604255 [TBL] [Abstract][Full Text] [Related]
15. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS Front Immunol; 2020; 11():1112. PubMed ID: 32595636 [TBL] [Abstract][Full Text] [Related]
16. The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice. Alipour S; Mahdavi A; Abdoli A Pathog Dis; 2017 Mar; 75(2):. PubMed ID: 28175274 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant. Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866 [TBL] [Abstract][Full Text] [Related]
18. Pseudo-mannosylated DC-SIGN ligands as potential adjuvants for HIV vaccines. Berzi A; Varga N; Sattin S; Antonazzo P; Biasin M; Cetin I; Trabattoni D; Bernardi A; Clerici M Viruses; 2014 Jan; 6(2):391-403. PubMed ID: 24473338 [TBL] [Abstract][Full Text] [Related]
19. Novel adjuvants for B cell immune responses. Loré K; Karlsson Hedestam GB Curr Opin HIV AIDS; 2009 Sep; 4(5):441-6. PubMed ID: 20048709 [TBL] [Abstract][Full Text] [Related]
20. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Olive C Expert Rev Vaccines; 2012 Feb; 11(2):237-56. PubMed ID: 22309671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]